Globus Medical, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GMED research report →
Range $78 – $100
Price Chart
About the company
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide.
- CEO
- Keith W. Pfeil
- IPO
- 2012
- Employees
- 6,000
- HQ
- Audubon, PA, US
Get TickerSpark's AI analysis on GMED
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $8.86B
- P/E
- 16.57
- Fwd P/E
- 13.43
- PEG
- 0.51
- P/S
- 2.89
- P/B
- 1.92
- EV/EBITDA
- 8.89
- Div Yield
- 0.00%
- Gross Margin
- 70.07%
- Op Margin
- 22.14%
- Net Margin
- 17.76%
- ROE
- 11.82%
- ROIC
- 10.94%
Latest fiscal year · YoY change
- Revenue
- $2.94B+16.7%
- Gross Profit
- $1.98B+33.5%
- Op Income
- $479.80M
- Net Income
- $537.90M+422.3%
- EPS
- $3.98+423.7%
- OCF Growth
- +44.7%
- FCF Growth
- +45.3%
- 52W High
- $101.40
- 52W Low
- $66.63
- 50D MA
- $76.12
- 200D MA
- $82.33
- Beta
- 0.96
- RSI (14)
- 35
- Avg Volume
- 1.62M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Globus Medical delivered record free cash flow and margin expansion in Q3, but lower-than-expected Spine launch timing and a delayed Nevro recovery forced a cut to 2026 revenue guidance.· November 5, 2026
- Q3 revenue was $763.7 million, down 0.7% reported and 0.5% constant currency; non-GAAP EPS was $1.23, up 4% year over year.
- Adjusted gross margin reached 69.5%, up 140 basis points year over year and the eighth straight quarter of sequential expansion.
- Base business revenue excluding Nevro was $690 million, up 3%, while Nevro fell 25.7% to $73.7 million.
- Management cut full-year 2026 revenue guidance to $3.09 billion from $3.18 billion-$3.22 billion, but kept non-GAAP EPS guidance at $4.95-$5.05.
- New products including SCRIPT, XLIF Prone, EIQ and HFX Elite are positioned as the main 2027 growth drivers, alongside better rep recruiting and Enabling Technologies pull-through.
Third-quarter 2026 revenue was $763.7 million, down 0.7% as reported and down 0.5% on a constant-currency basis. GAAP net income was $141.2 million, or $1.04 per diluted share, and non-GAAP net income was $167 million, or $1.23 per diluted share, up 4.4% year over year. GAAP gross margin was 66.7% versus 64.2% a year ago; adjusted gross margin was 69.5% versus 68.1%, up 140 basis points. Total company adjusted EBITDA margin was 34.3% versus 32.8% a year ago. Free cash flow was a record $225 million, and operating cash flow was $265 million. For 2026, management lowered revenue guidance to $3.09 billion from $3.18 billion-$3.22 billion, implying 5.1% growth, and reaffirmed non-GAAP diluted EPS guidance of $4.95-$5.05.
Keith Pfeil framed the quarter as a timing issue more than a demand issue, saying the main misses came from delayed new product launches and weaker-than-expected competitive recruiting. He was upbeat about the 2027 setup, emphasizing SCRIPT, XLIF Prone, EIQ, and a more stable Nevro business as catalysts, while also highlighting ongoing M&A activity and a broader push into cranial neurosurgery and digital surgical intelligence. His tone was confident but candid, repeatedly noting execution could have been better in 2026 while stressing the long-term strategy is intact.
Kyle Klin focused on the financial upside from margin expansion and cash generation, citing adjusted gross margin of 69.5%, adjusted EBITDA margin of 34.3%, operating cash flow of $265 million and free cash flow of $225 million. He noted cash and marketable securities of $871.2 million at quarter end, with $279 million of share repurchases year to date and an additional $500 million authorization approved by the board. He also said R&D was $34.5 million, or 4.5% of sales, and expects R&D dollars to rise over the next several quarters, while 2026 adjusted gross margin is still expected to land between 69% and 70%.
Analysts pressed on whether the company was seeing a softer market, how much delayed Spine launches hurt Q3, and whether competitive recruiting or retention issues were limiting growth. Management declined to quantify the Q3 revenue impact, saying the miss was mainly timing-related and tied to new product delays and weaker rep recruiting, not broad market softness. They also said the U.S. Spine manufacturing issues are largely worked through, that SCRIPT has generated strong surgeon interest, and that most of the 2027 upside depends on those launches, Nevro stabilization, and Enabling Technologies conversion to a more flexible capital model.
The call showed a clear path to stronger 2027 growth if delayed Spine launches ramp as planned, Nevro stabilizes, and Enabling Technologies continues to grow. Management pointed to 24% Enabling Technologies growth, 19% Trauma growth, strong surgeon interest in SCRIPT, and over 145,000 robotic cases as evidence that core platforms are gaining traction.
The near-term story is weaker because 2026 guidance was cut, Q4 is expected to decline mid-single digits, and management said SCRIPT and other launches will not contribute meaningfully until 2027. Nevro remains a drag, with revenue down 25.7% and trial volume recovery slower than expected, while international weakness, especially Japan, and lower-than-expected competitive recruiting also weighed on results.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.3%
- Shares Outstanding
- 132.47M
- Float Shares
- 131.53M
of shares held by institutions
618 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for GMED, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Gilbert CisnerosHouse · CA31 | Buy | Sep 3, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Aug 19, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 3, 26 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 17, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jul 10, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Sell | Jun 24, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Apr 9, 25 | Filing → |
| Josh GottheimerHouse · NJ05 | Buy | Apr 3, 23 | Filing → |
| Daniel GoldmanHouse · NY10 | Sell | Mar 6, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Feb 8, 23 | Filing → |
| Josh GottheimerHouse · NJ05 | Sell | Jan 11, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Aug 23, 22 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Jun 27, 22 | Filing → |
| Ro KhannaHouse · CA17 | Buy | May 10, 22 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 10.91M | ▲ 99.32K |
| Vanguard Group Inc | 10.55M | ▼ 56.29K |
| Jupiter Topco LLC | 8.20M | ▲ 8.20M |
| Janus Henderson Group Ltd. | 7.62M | ▲ 328.22K |
| Vanguard Capital Management LLC | 5.08M | ▼ 31.97K |
| Vanguard Portfolio Management LLC | 4.87M | ▼ 128.02K |
| State Street Corp | 3.72M | ▲ 4.52K |
| Boston Partners | 3.42M | ▲ 1.86M |
| Kayne Anderson Rudnick Investment Management LLC | 3.20M | ▼ 1.08M |
| Jpmorgan Chase & Co | 3.16M | ▲ 414.67K |
| Dimensional Fund Advisors LP | 3.01M | ▲ 638.13K |
| Swedbank Ab | 2.88M | ▲ 2.36M |
Held by 509 ETFs
Biggest fund positions in GMED by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 10, 26 | TOBIN JAMES R | other | 5,208 |
| Nov 10, 26 | TOBIN JAMES R | other | 21,458 |
| Nov 10, 26 | TOBIN JAMES R | other | 15,000 |
| Nov 10, 26 | TOBIN JAMES R | sell | 37,662 |
| Nov 10, 26 | TOBIN JAMES R | other | 5,208 |
| Nov 10, 26 | TOBIN JAMES R | sell | 4,004 |
| Nov 10, 26 | TOBIN JAMES R | other | 15,000 |
| Nov 10, 26 | TOBIN JAMES R | other | 21,458 |
| Nov 4, 26 | RHOADS ANN D | sell | 5,000 |
| Sep 15, 26 | TOBIN JAMES R | other | 15,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our GMED coverage
Recent articles, reports, and earnings notes.
No research on GMED yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GMED report →Globus Medical, Inc. (GMED) Presents at Jefferies Global Healthcare Conference 2026 Transcript
seekingalpha.com · Nov 18
Globus Medical to Participate in Jefferies Global Healthcare Conference
globenewswire.com · Nov 9
Globus Medical Q3 Earnings Call Highlights
marketbeat.com · Nov 7
GMED Q3 Earnings Call Highlights Guidance Cut and 2027 Reset
zacks.com · Nov 6
Globus Medical, Inc. (GMED) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Compared to Estimates, Globus Medical (GMED) Q3 Earnings: A Look at Key Metrics
zacks.com · Nov 5
Globus Medical (GMED) Q3 Earnings Top Estimates
zacks.com · Nov 5
Globus Medical Reports Third Quarter 2026 Results and Announces a $500 Million Increase to the Share Repurchase Program
globenewswire.com · Nov 5
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.